|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | |||||||
  International Journal of DermatologyVolume 43 Issue 2, Pages 151 - 154 Published Online: 6 Feb 2004 Journal compilation © 2010 International Society of Dermatology The Official Journal of the International Society of Dermatology
Abstract | References | Full Text: HTML, PDF (Size: 177K) | Related Articles | Citation Tracking  Pharmacology and therapeutics Therapeutic potential of azithromycin in rosacea Copyright
© 2004 The International Society of Dermatology ABSTRACTBackground Systemic antibiotics currently used in the treatment of rosacea are sometimes associated with uncomfortable side-effects. Therefore, a need for an effective agent with few side-effects and good patient compliance exists. Azithromycin, a macrolide antibiotic with prolonged mode of action, has recently been found to be an effective alternative in the treatment of inflammatory acne. We planned a study to evaluate the efficacy and safety of azithromycin in rosacea. Methods An open-labeled study was performed in a population of 18 patients, with Plewig-Kligman stage 2 rosacea. Patients were given oral azithromycin for 12 weeks in decreasing doses. Results Fourteen subjects completed the trial. The treatment produced therapeutic benefits with regard to total scores as well as inflammatory lesion scores. At the end of 12 weeks, there was a 75% decrease in total scores (P < 0.001) and an 89% decrease in inflammatory lesion scores compared with basal values. Improvement continued during the 4 weeks after treatment. Adverse effects were minimal and well tolerated in most patients. Conclusion Azithromycin is a promising agent in the treatment of rosacea with its few side-effects and good patient compliance. | 
|
